Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jul 20;11:1221578. doi: 10.3389/fcell.2023.1221578

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 Wehrli, Galdadas, Voirol, Smieško, Cambet, Jaquet, Guerrier, Gervasio, Nef and Rahban.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Steroid screening results and steroid selection workflow. (A) Venn diagram showing the selection of steroids. A total of 10 steroids with the most potent activating and P4-antagonizing activity were selected. NS: non-steroids; S: steroids; OT: off-targets. Graphical representation of the 90 steroids for their ability to increase the [Ca²⁺]_i and inhibit in (B) the P4- and in (C) the PGE1-induced Ca²⁺ response. Data are expressed as the mean percentage of maximal amplitude ∆F/F0, triggered by each steroid at 10 µM and normalized to P4 response at 2 μM, before (activation, purple) or after the addition of P4 or PGE1 (inhibition in black).